• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌症耐药性中的新兴靶点。

Emerging targets in cancer drug resistance.

作者信息

Kumar Shashank, Kushwaha Prem Prakash, Gupta Sanjay

机构信息

School of Basic and Applied Sciences, Department of Biochemistry and Microbial Sciences, Central University of Punjab, Bathinda 151001, India.

Department of Urology, Case Western Reserve University, Cleveland, Ohio 44106, USA.

出版信息

Cancer Drug Resist. 2019 Jun 19;2(2):161-177. doi: 10.20517/cdr.2018.27. eCollection 2019.

DOI:10.20517/cdr.2018.27
PMID:35582722
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8992633/
Abstract

Drug resistance is a complex phenomenon that frequently develops as a failure to chemotherapy during cancer treatment. Malignant cells increasingly generate resistance to various chemotherapeutic drugs through distinct mechanisms and pathways. Understanding the molecular mechanisms involved in drug resistance remains an important area of research for identification of precise targets and drug discovery to improve therapeutic outcomes. This review highlights the role of some recent emerging targets and pathways which play critical role in driving drug resistance.

摘要

耐药性是一种复杂的现象,在癌症治疗期间经常作为化疗失败而出现。恶性细胞通过不同的机制和途径越来越多地对各种化疗药物产生耐药性。了解耐药性所涉及的分子机制仍然是一个重要的研究领域,用于确定精确的靶点和发现药物以改善治疗效果。本综述强调了一些最近出现的靶点和途径在驱动耐药性方面所起的关键作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f24e/8992633/52b40ef7b485/cdr-2-161.fig.3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f24e/8992633/dece96b87483/cdr-2-161.fig.1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f24e/8992633/f5d198396c6a/cdr-2-161.fig.2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f24e/8992633/52b40ef7b485/cdr-2-161.fig.3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f24e/8992633/dece96b87483/cdr-2-161.fig.1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f24e/8992633/f5d198396c6a/cdr-2-161.fig.2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f24e/8992633/52b40ef7b485/cdr-2-161.fig.3.jpg

相似文献

1
Emerging targets in cancer drug resistance.癌症耐药性中的新兴靶点。
Cancer Drug Resist. 2019 Jun 19;2(2):161-177. doi: 10.20517/cdr.2018.27. eCollection 2019.
2
Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer.Keap1的基因改变赋予胆囊癌组成型Nrf2激活及化疗抗性。
Gastroenterology. 2008 Oct;135(4):1358-1368, 1368.e1-4. doi: 10.1053/j.gastro.2008.06.082. Epub 2008 Jul 3.
3
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.RAF/MEK/ERK和PI3K/PTEN/AKT信号通路在恶性转化和耐药中的作用。
Adv Enzyme Regul. 2006;46:249-79. doi: 10.1016/j.advenzreg.2006.01.004. Epub 2006 Jul 18.
4
Role of FOXO protein's abnormal activation through PI3K/AKT pathway in platinum resistance of ovarian cancer.FOXO蛋白通过PI3K/AKT途径异常激活在卵巢癌铂耐药中的作用
J Obstet Gynaecol Res. 2021 Jun;47(6):1946-1957. doi: 10.1111/jog.14753. Epub 2021 Apr 7.
5
Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease.氧化还原应激源、营养信号和能量状态对转录因子Nrf2的激活机制,以及其减轻退行性疾病的途径。
Free Radic Biol Med. 2015 Nov;88(Pt B):108-146. doi: 10.1016/j.freeradbiomed.2015.06.021. Epub 2015 Jun 27.
6
FOXO and FOXM1 in cancer: the FOXO-FOXM1 axis shapes the outcome of cancer chemotherapy.FOXO 和 FOXM1 在癌症中的作用:FOXO-FOXM1 轴决定癌症化疗的结果。
Curr Drug Targets. 2011 Aug;12(9):1256-66. doi: 10.2174/138945011796150244.
7
Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance.叉头框转录因子 FOXO-FOXM1 轴在癌症和耐药性中的作用。
Front Med. 2012 Dec;6(4):376-80. doi: 10.1007/s11684-012-0228-0. Epub 2012 Nov 3.
8
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.由于 Raf/MEK/ERK 和 PI3K/PTEN/Akt/mTOR 信号通路中的突变而导致的治疗抵抗。
J Cell Physiol. 2011 Nov;226(11):2762-81. doi: 10.1002/jcp.22647.
9
FOXO Signaling Pathways as Therapeutic Targets in Cancer.FOXO 信号通路作为癌症治疗靶点。
Int J Biol Sci. 2017 Jul 6;13(7):815-827. doi: 10.7150/ijbs.20052. eCollection 2017.
10
Overview of Evidence-Based Chemotherapy for Oral Cancer: Focus on Drug Resistance Related to the Epithelial-Mesenchymal Transition.口腔癌循证化疗概述:重点关注上皮-间质转化相关的耐药性。
Biomolecules. 2021 Jun 16;11(6):893. doi: 10.3390/biom11060893.

引用本文的文献

1
Cytotoxic naphtho- and benzofurans from an endophytic fungus Epicoccum nigrum Ann-B-2 associated with Annona squamosa fruits.与番荔枝果实相关的内生真菌层出镰刀菌 Ann-B-2 中具有细胞毒性的萘并呋喃和苯并呋喃。
Sci Rep. 2024 Feb 28;14(1):4940. doi: 10.1038/s41598-024-55168-5.
2
Drug resistance mechanisms in cancers: Execution of pro-survival strategies.癌症中的耐药机制:促生存策略的实施
J Biomed Res. 2024 Feb 28;38(2):95-121. doi: 10.7555/JBR.37.20230248.
3
Understanding Cancer's Defense against Topoisomerase-Active Drugs: A Comprehensive Review.

本文引用的文献

1
PATRI, a Genomics Data Integration Tool for Biomarker Discovery.PATRI,一种用于生物标志物发现的基因组学数据集成工具。
Biomed Res Int. 2018 Jun 28;2018:2012078. doi: 10.1155/2018/2012078. eCollection 2018.
2
Low expression of KCNN3 may affect drug resistance in ovarian cancer.KCNN3 低表达可能影响卵巢癌的耐药性。
Mol Med Rep. 2018 Aug;18(2):1377-1386. doi: 10.3892/mmr.2018.9107. Epub 2018 May 31.
3
Delineating the HMGB1 and HMGB2 interactome in prostate and ovary epithelial cells and its relationship with cancer.描绘前列腺和卵巢上皮细胞中的HMGB1和HMGB2相互作用组及其与癌症的关系。
了解癌症对拓扑异构酶活性药物的防御机制:全面综述。
Cancers (Basel). 2024 Feb 6;16(4):680. doi: 10.3390/cancers16040680.
4
Understanding the Combined Effects of High Glucose Induced Hyper-Osmotic Stress and Oxygen Tension in the Progression of Tumourigenesis: From Mechanism to Anti-Cancer Therapeutics.了解高葡萄糖诱导的高渗应激与氧气张力在肿瘤发生发展中的联合效应:从机制到抗癌治疗。
Cells. 2023 Mar 7;12(6):825. doi: 10.3390/cells12060825.
5
Development of Polymersomes Co-Delivering Doxorubicin and Melittin to Overcome Multidrug Resistance.聚合物囊泡共递送多柔比星和蜂毒素以克服多药耐药性的研究进展。
Molecules. 2023 Jan 21;28(3):1087. doi: 10.3390/molecules28031087.
6
Label-Free Quantitative Proteomics Analysis of Adriamycin Selected Multidrug Resistant Human Lung Cancer Cells.阿霉素筛选的多药耐药人肺癌细胞的无标记定量蛋白质组学分析。
Biomolecules. 2022 Oct 1;12(10):1401. doi: 10.3390/biom12101401.
7
Multidrug Resistance of Cancer Cells and the Vital Role of P-Glycoprotein.癌细胞的多药耐药性与P-糖蛋白的重要作用。
Life (Basel). 2022 Jun 15;12(6):897. doi: 10.3390/life12060897.
8
Targeting Breast Cancer-Derived Stem Cells by Dietary Phytochemicals: A Strategy for Cancer Prevention and Treatment.通过膳食植物化学物质靶向乳腺癌衍生干细胞:一种癌症预防和治疗策略。
Cancers (Basel). 2022 Jun 10;14(12):2864. doi: 10.3390/cancers14122864.
9
Decrypting a path based approach for identifying the interplay between PI3K and GSK3 signaling cascade from the perspective of cancer.从癌症角度解密一种基于路径的方法,以识别PI3K和GSK3信号级联之间的相互作用。
Genes Dis. 2022 Feb 22;9(4):868-888. doi: 10.1016/j.gendis.2021.12.025. eCollection 2022 Jul.
10
"Pharmacogenetics of Cancer" - special issue.《癌症的药物遗传学》——特刊
Cancer Drug Resist. 2020 Feb 20;3(2):225-231. doi: 10.20517/cdr.2020.10. eCollection 2020.
Oncotarget. 2018 Apr 10;9(27):19050-19064. doi: 10.18632/oncotarget.24887.
4
Annexin A2-mediated cancer progression and therapeutic resistance in nasopharyngeal carcinoma.膜联蛋白 A2 介导体鼻咽癌细胞进展和治疗耐药性。
J Biomed Sci. 2018 Mar 29;25(1):30. doi: 10.1186/s12929-018-0430-8.
5
Dysregulation of NRF2 in Cancer: from Molecular Mechanisms to Therapeutic Opportunities.癌症中NRF2的失调:从分子机制到治疗机遇
Biomol Ther (Seoul). 2018 Jan 1;26(1):57-68. doi: 10.4062/biomolther.2017.195.
6
The molecular mechanisms of chemoresistance in cancers.癌症中化疗耐药的分子机制。
Oncotarget. 2017 Jul 6;8(35):59950-59964. doi: 10.18632/oncotarget.19048. eCollection 2017 Aug 29.
7
Protein phosphorylation and its role in the regulation of Annexin A2 function.蛋白质磷酸化及其在调节膜联蛋白 A2 功能中的作用。
Biochim Biophys Acta Gen Subj. 2017 Nov;1861(11 Pt A):2515-2529. doi: 10.1016/j.bbagen.2017.08.024. Epub 2017 Sep 1.
8
Annexin A2 could enhance multidrug resistance by regulating NF-κB signaling pathway in pediatric neuroblastoma.膜联蛋白 A2 可通过调节 NF-κB 信号通路增强小儿神经母细胞瘤的多药耐药性。
J Exp Clin Cancer Res. 2017 Aug 16;36(1):111. doi: 10.1186/s13046-017-0581-6.
9
Cell matrix adhesions in cancer: The proteins that form the glue.癌症中的细胞-基质黏附:构成“胶水”的蛋白质。
Oncotarget. 2017 Jul 18;8(29):48471-48487. doi: 10.18632/oncotarget.17265.
10
EGFR inhibition in NSCLC: New findings…. and opened questions?非小细胞肺癌中的表皮生长因子受体抑制:新发现……和未解决的问题?
Crit Rev Oncol Hematol. 2017 Apr;112:126-135. doi: 10.1016/j.critrevonc.2017.02.009. Epub 2017 Feb 16.